Bibliographie

Bibliographie
1 Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997 ; 337 : 1641-7.
2 Delmas PD, Ensrud KE, Harris S, et al. Raloxifene therapy for 3 years reduces the risk of incident vertebral fractures in postmenopausal women. Calc Tiss Int 1999 ; 64 (Suppl.1) : abstract O-27.
3 Markiewicz L, Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestogenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium. J Steroid Biochem 1990 ; 35 : 535-41.
4 Klosterboer HJ : Tibolone and its metabolites : Pharmacology, tissue specificity and effects in animal models of tumors. Gynecol Endocrinol 1997 ; 11 (Suppl. 1) : 63-9.
5 McClung MR. New data on oral 17b - estradiol + NETA in prevention of postemenopausal bone loss. New Combination alternatives in HRT, a satellite symposium. Europ Congress Osteoporosis Berlin, 1998.
6 Genant HK, Lucas J, Weiss St, et al. Low-dose esterified estrogen therapy. Arch Intern Med 1997 ; 157 : 2609-15.
7 Ginsburg J. Tibolone and the endometrium – tibolone and bleeding. J Menopause 1999 ; 1 (Suppl. 1) : 9-12.
8 Hammar M, et al. A double-blind, randomized trial comparing the effect of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998 ; 105 : 904-11.
9 Lippuner K, et al. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17b-Estradiol and dydrogesterone. J Bone Miner Res 1997 ; 12 : 806-12.
10 Ginsburg J, Prelevic G, Butler D, Okolo S. Clinical experience with tibolone (Livial ®) over 8 years. Maturitas 1995 ; 21 : 71-6.
11 Bjarnason NH, et al : Tibolone : Prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996 ; 81 : 2419-22.
12 Berning B, Kuijk CV, Kuiper JW, Coelingh Bennink HJT, Kicovic PM, Fauser BC. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women : A two-year randomized, placebo-controlled stu-
dy. Bone 1996 ; 19 : 395-9.
13 Rymer J, et al. Effect of tibolone on postmenopausal bone loss. Osteoporos Int 1994 ; 4 : 314-9.
14 Thiébaud D, Bigler JM, Rentereia S, et al. A 3-year study of prevention of postmenopausal bone loss : Conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. Climateric 1998 ; 1 : 202-10.
15 Prevelic GM, et al. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. Gynecol Endocrinol 1996 ; 10 : 413-20.
16 The Writing Group of the PEPI trial. Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. Effects of hormone therapy on bone mi-neral density. JAMA 1996 ; 276 : 1389-96.
17 Eriksen EF, et al. European and North American experience with HRT for the prevention of osteoporosis. Bone 1996 ; 19 : 179S-83S.
18 Studd J, et al. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998 ; 92 : 574-9.
19 Geusens P, Dequeker J, Gielen J, Schot LPC. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991 ; 13 : 155-62.
20 Hänggi W, Lippuner K, Riesen W, Jaeger P, Birkhäuser MH. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a) : A randomized trial. Br J Obstet Gynaecol 1997 ; 104 : 708-17.
Pour revue : Moore RA. Livial : A review of clinical studies. Br J Obstet Gynaecol 1999 ; 106 (Suppl. 19): 1-21.